BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15363992)

  • 1. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.
    Yuyama H; Noguchi Y; Fujimori A; Ukai M; Fujiyasu N; Ohtake A; Sato S; Sudoh K; Sasamata M; Miyata K
    Eur J Pharmacol; 2004 Sep; 498(1-3):171-7. PubMed ID: 15363992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
    Sudoh K; Yuyama H; Noguchi Y; Fujimori A; Ukai M; Ohtake A; Sato S; Sasamata M; Miyata K
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S390-3. PubMed ID: 15838329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist.
    Yuyama H; Sanagi M; Koakutsu A; Mori M; Fujimori A; Harada H; Sudoh K; Miyata K
    Eur J Pharmacol; 2003 Sep; 478(1):61-71. PubMed ID: 14555186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract.
    Ukai M; Yuyama H; Fujimori A; Koakutsu A; Sanagi M; Ohtake A; Sato S; Sudoh K; Sasamata M; Miyata K
    Eur J Pharmacol; 2008 Feb; 580(3):394-400. PubMed ID: 18078923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ca2+ signalling by endothelin receptors in rat and human cultured airway smooth muscle cells.
    Maxwell MJ; Goldie RG; Henry PJ
    Br J Pharmacol; 1998 Dec; 125(8):1768-78. PubMed ID: 9886769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain.
    Yuyama H; Koakutsu A; Fujiyasu N; Tanahashi M; Fujimori A; Sato S; Shibasaki K; Tanaka S; Sudoh K; Sasamata M; Miyata K
    Eur J Pharmacol; 2004 May; 492(2-3):177-82. PubMed ID: 15178362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes.
    Sachidanandam K; Elgebaly MM; Harris AK; Hutchinson JR; Mezzetti EM; Portik-Dobos V; Ergul A
    Am J Physiol Heart Circ Physiol; 2008 Jun; 294(6):H2743-9. PubMed ID: 18424628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes.
    Harris AK; Elgebaly MM; Li W; Sachidanandam K; Ergul A
    Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1213-9. PubMed ID: 18287215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of selective and non-selective endothelin receptor blockade on ET-1-induced pressor response in the hamster.
    Honoré JC; Fecteau MH; Wessale JL; D'Orléans-Juste P
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S68-71. PubMed ID: 15838362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of YM598, a selective endothelin ETA receptor antagonist, on endothelin-1-induced bone formation.
    Someya A; Yuyama H; Fujimori A; Ukai M; Fukushima S; Sasamata M
    Eur J Pharmacol; 2006 Aug; 543(1-3):14-20. PubMed ID: 16843458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal protective effect of YM598, a selective endothelin type A receptor antagonist.
    Sugimoto K; Fujimori A; Yuyama H; Tahara A; Fujimura A
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S451-4. PubMed ID: 15838346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
    Battistini B; Verreault M; Ayach B; Blouin A; Cernacek P; Jeng AY; Wessale J; Opgenorth T; Tsang J
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S386-9. PubMed ID: 15838327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice.
    Yuyama H; Koakutsu A; Fujiyasu N; Fujimori A; Sato S; Shibasaki K; Tanaka S; Sudoh K; Sasamata M; Miyata K
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S479-82. PubMed ID: 15838353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways.
    Maguire JJ; Kuc RE; Pell VR; Green A; Brown M; Kumar S; Wehrman T; Quinn E; Davenport AP
    Life Sci; 2012 Oct; 91(13-14):544-9. PubMed ID: 22480514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distortion of K
    Angus JA; Hughes RJA; Wright CE
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers.
    Gregan B; Schaefer M; Rosenthal W; Oksche A
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S30-3. PubMed ID: 15838305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Participation of endogenous endothelin and ETA receptor in premicturition contractions in rats with bladder outlet obstruction.
    Ukai M; Yuyama H; Noguchi Y; Someya A; Okutsu H; Watanabe M; Yoshino T; Ohtake A; Suzuki M; Sato S; Sasamata M
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Jun; 373(3):197-203. PubMed ID: 16736156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
    Liu G; Henry KJ; Szczepankiewicz BG; Winn M; Kozmina NS; Boyd SA; Wasicak J; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
    J Med Chem; 1998 Aug; 41(17):3261-75. PubMed ID: 9703472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
    Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Sudoh K; Sasamata M; Miyata K
    Eur J Pharmacol; 2004 Aug; 496(1-3):129-39. PubMed ID: 15288584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo.
    Thai TL; Arendshorst WJ
    Am J Physiol Renal Physiol; 2008 Aug; 295(2):F360-8. PubMed ID: 18524860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.